-
Je něco špatně v tomto záznamu ?
Lycopene increases metabolic activity of rat liver CYP2B, CYP2D and CYP3A
K. Nosková, G. Dovrtělová, O. Zendulka, M. Strakošová, O. Peš, J. Juřica,
Jazyk angličtina Země Švýcarsko
Typ dokumentu časopisecké články
- MeSH
- antioxidancia aplikace a dávkování farmakologie MeSH
- jaterní mikrozomy účinky léků enzymologie MeSH
- krysa rodu rattus MeSH
- lykopen aplikace a dávkování farmakologie MeSH
- potkani Wistar MeSH
- systém (enzymů) cytochromů P-450 účinky léků metabolismus MeSH
- vztah mezi dávkou a účinkem léčiva MeSH
- zvířata MeSH
- Check Tag
- krysa rodu rattus MeSH
- mužské pohlaví MeSH
- zvířata MeSH
- Publikační typ
- časopisecké články MeSH
BACKGROUND: Lycopene as a naturally occurring carotenoid is a common part of the human diet. Several beneficial properties of lycopene have been identified, with the most studied being anti-cancer and antioxidant activity. However, no evidence of possible drug-drug or drug-food supplement interactions has been found. METHODS: We studied the in vivo effect of lycopene on the selected rat liver cytochromes P450 (CYPs): CYP1A2, CYP2B, CYP2C11, CYP2C6, CYP2D, and CYP3A. Lycopene was administered to rats intragastrically at doses of 4, 20, and 100 mg/kg/day for 10 consecutive days. Total protein content, P450 Content, and metabolic activity of selected CYPs were evaluated in the rat liver microsomal fraction. RESULTS: Increased CYP2B, CYP2D, and CYP3A metabolic activities were observed in animals treated with the lycopene dose of 100 mg/kg/day. The content of CYP3A1 protein was increased by the dose of 100 mg/kg/day and CYP3A2 protein was increased by all administered doses of lycopene. CONCLUSION: The results of our study indicate that lycopene increased the metabolic activity of enzymes that are orthologues to the most clinically important human enzymes involved in xenobiotic metabolism. The risk of pharmacokinetic interactions between lycopene dietary supplements and co-administered drugs should be evaluated.
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc20028568
- 003
- CZ-PrNML
- 005
- 20210114154302.0
- 007
- ta
- 008
- 210105s2020 sz f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1007/s43440-019-00007-y $2 doi
- 035 __
- $a (PubMed)32016858
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a sz
- 100 1_
- $a Nosková, Kristýna $u Department of Pharmacology, Faculty of Medicine, Masaryk University, Kamenice 5, 625 00, Brno, Czech Republic.
- 245 10
- $a Lycopene increases metabolic activity of rat liver CYP2B, CYP2D and CYP3A / $c K. Nosková, G. Dovrtělová, O. Zendulka, M. Strakošová, O. Peš, J. Juřica,
- 520 9_
- $a BACKGROUND: Lycopene as a naturally occurring carotenoid is a common part of the human diet. Several beneficial properties of lycopene have been identified, with the most studied being anti-cancer and antioxidant activity. However, no evidence of possible drug-drug or drug-food supplement interactions has been found. METHODS: We studied the in vivo effect of lycopene on the selected rat liver cytochromes P450 (CYPs): CYP1A2, CYP2B, CYP2C11, CYP2C6, CYP2D, and CYP3A. Lycopene was administered to rats intragastrically at doses of 4, 20, and 100 mg/kg/day for 10 consecutive days. Total protein content, P450 Content, and metabolic activity of selected CYPs were evaluated in the rat liver microsomal fraction. RESULTS: Increased CYP2B, CYP2D, and CYP3A metabolic activities were observed in animals treated with the lycopene dose of 100 mg/kg/day. The content of CYP3A1 protein was increased by the dose of 100 mg/kg/day and CYP3A2 protein was increased by all administered doses of lycopene. CONCLUSION: The results of our study indicate that lycopene increased the metabolic activity of enzymes that are orthologues to the most clinically important human enzymes involved in xenobiotic metabolism. The risk of pharmacokinetic interactions between lycopene dietary supplements and co-administered drugs should be evaluated.
- 650 _2
- $a zvířata $7 D000818
- 650 _2
- $a antioxidancia $x aplikace a dávkování $x farmakologie $7 D000975
- 650 _2
- $a systém (enzymů) cytochromů P-450 $x účinky léků $x metabolismus $7 D003577
- 650 _2
- $a vztah mezi dávkou a účinkem léčiva $7 D004305
- 650 _2
- $a lykopen $x aplikace a dávkování $x farmakologie $7 D000077276
- 650 _2
- $a mužské pohlaví $7 D008297
- 650 _2
- $a jaterní mikrozomy $x účinky léků $x enzymologie $7 D008862
- 650 _2
- $a krysa rodu Rattus $7 D051381
- 650 _2
- $a potkani Wistar $7 D017208
- 655 _2
- $a časopisecké články $7 D016428
- 700 1_
- $a Dovrtělová, Gabriela $u RECETOX Centre, Masaryk University, Brno, Czech Republic.
- 700 1_
- $a Zendulka, Ondřej $u Department of Pharmacology, Faculty of Medicine, Masaryk University, Kamenice 5, 625 00, Brno, Czech Republic.
- 700 1_
- $a Strakošová, Markéta $u Department of Pharmacology, Faculty of Medicine, Masaryk University, Kamenice 5, 625 00, Brno, Czech Republic.
- 700 1_
- $a Peš, Ondřej $u Department of Biochemistry, Faculty of Medicine, Masaryk University, Brno, Czech Republic.
- 700 1_
- $a Juřica, Jan $u Department of Pharmacology, Faculty of Medicine, Masaryk University, Kamenice 5, 625 00, Brno, Czech Republic. jurica@med.muni.cz. Masaryk Memorial Cancer Institute, Brno, Czech Republic. jurica@med.muni.cz. Department of Human Pharmacology and Toxicology, Faculty of Pharmacy, University of Veterinary and Pharmaceutical Sciences, Brno, Czech Republic. jurica@med.muni.cz.
- 773 0_
- $w MED00165879 $t Pharmacological reports : PR $x 1734-1140 $g Roč. 72, č. 1 (2020), s. 156-165
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/32016858 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y a $z 0
- 990 __
- $a 20210105 $b ABA008
- 991 __
- $a 20210114154259 $b ABA008
- 999 __
- $a ok $b bmc $g 1608903 $s 1119748
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2020 $b 72 $c 1 $d 156-165 $e 20200113 $i 1734-1140 $m Pharmacol. Reports $n Pharmacol. Rep. $x MED00165879
- LZP __
- $a Pubmed-20210105
